|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A Body - Mind - Spirit Model in Health显示文摘 | Cecilia Chan Petula S etal | 2002 | Social Work in Health Care2002，34，3： | 1 |
| 2 | Treatment response in enteropathy associated T ‐cell lymphoma; survival in a large multicenter cohort显示文摘 | Petula Nijeboer Laura R. de Baaij Otto Visser Birgit I. Witte Saskia A.G.M. Cillessen Chris J. Mulder Gerd Bouma | 2015 | Am. J. Hematol2015，，6： | 1 |
| 3 | Surgery in (pre)malignant celiac disease显示文摘AIM: To report the outcome of surgery in patients with(pre)malignant conditions of celiac disease(CD) and the impact on survival.METHODS: A total of 40 patients with(pre)malignant conditions of CD,ulcerative jejunitis(n = 5) and enteropathy associated T-cell lymphoma(EATL)(n = 35),who underwent surgery between 2002 and 2013 were retrospectively evaluated. Data on indications,operative procedure,post-operative morbidity and mortali ty,adjuvant therapy and overal l survival(OS) were collected. Eleven patients with EATL who underwent chemotherapy without resection were included as a control group for survival analysis. Patients were followed-up every three months during the first year and at 6-mo intervals thereafter.RESULTS: Mean age at resection was 62 years. The majority of patients(63%) underwent elective laparotomy. Functional stenosis(n = 1 3) and perforation(n = 12) were the major indications for surgery. In 70% of patients radical resection wasperformed. Early postoperative complications,mainly due to leakage or sepsis,occurred in 14/40(35%) of patients. Eight patients required reoperation. More patients who underwent resection in the acute setting(n = 3,20%) died compared to patients treated in the elective setting. With a median follow-up of 20 mo,seven patients(18%) required reoperation due to long-term complications. Significantly more patients who underwent acute surgery could not be treated with adjuvant chemotherapy. Patients who first underwent surgical resection showed significantly better OS than patients who received chemotherapy without resection.CONCLUSION: Although the complication rate is high,the preferred first step of treatment in(pre)malignant CD consists of local resection as early as possible to improve survival. | Jolanda MW van de Water Petula Nijeboer Laura R de Baaij Jessy Zegers Gerd Bouma Otto J Visser Donald L van der Peet Chris JJ Mulder Wilhelmus JHJ Meijerink | 2015 | World Journal of Gastroenterology2015，21，43： | 0 |
| 4 | Hematopoietic stem cell transplantation for non-malignant gastrointestinal diseases显示文摘Both,autologous and allogeneic hematopoietic stem cell transplantation(HSCT)can be used to cure or ameliorate a variety of malignant and non-malignant diseases.The rationale behind this strategy is based on the concept of immunoablation using high-dose chemotherapy,with subsequent regeneration of naive T-lymphocytes derived from reinfused hematopoietic progenitor cells.In addition,the use of HSCT allows for the administration of high-dose chemotherapy(whether or not combined with immunomodulating agents such as antithymocyte globulin)resulting in a prompt remission in therapy-refractory patients.This review gives an update of the major areas of successful uses of HSCT in non-malignant gastrointestinal disorders.A Medline search has been conducted and all relevant published data were analyzed.HSCT has been proved successful in treating refractory Crohn’s disease(CD).Patientswith refractory celiac disease typeⅡand a high risk of developing enteropathy associated T-cell lymphoma have shown promising improvement.Data concerning HSCT and mesenchymal SCT in end-stage chronic liver diseases are encouraging.In refractory autoimmune gastrointestinal diseases high-dose chemotherapy followed by HSCT seems feasible and safe and might result in long-term improvement of disease activity.Mesenchymal SCT for a selected group of CD is promising and may represent a significant therapeutic alternative in treating fistulas in CD. | Abdulbaqi Al-toma Petula Nijeboer Gerd Bouma Otto Visser Chris JJ Mulder | 2014 | World Journal of Gastroenterology2014，20，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员